Novavax Receives Milestone Payment from Takeda Following COVID-19 Vaccine Approval in Japan

Novavax announces that approval of its COVID-19 vaccine in Japan triggers a milestone payment from Takeda. The vaccine uses a recombinant protein approach and nanoparticle technology, combined with a patented Matrix-M adjuvant to enhance the immune response. Novavax is advancing the development of other vaccine candidates, including a COVID-19-Influenza Combination vaccine and additional candidates. The COVID-19 vaccine and other candidates incorporate the company's proprietary Matrix-M adjuvant to stimulate higher levels of functional antibodies and induce a cellular immune response.